EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub‐Study of the FOLL12 Trial

Rexhep Durmo iD, Stephane Chauvie iD, Carla Minoia, Fabrizio Bergesio, Federico Fallanca, Simona Peano, Luigi Marcheselli, Antonella Anastasia, Carola Boccomini, Paolo Corradini, Jacopo Olivieri, Luca Arcaini und 21 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.27711 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Rexhep Durmo und 32 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine, Azienda USL IRCCS of Reggio Emilia, Reggio Emilia, Italy. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Tumor Burden. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione Italiana Linfomi (FIL), Fellowship for Indigenous Leadership.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Discordant results have been generated regarding the prognostic role of Total Metabolic Tumor Volume (TMTV) in Follicular Lymphoma (FL). The use of prospective data and the adoption of the newly defined standardized SUV4 method for calculating TMTV may generate stronger evidence. We conducted a pre‐planned post hoc analysis of the prospective multicenter randomized phase III FOLL12 trial for newly diagnosed high tumor burden FL (grade 1–3a), which mandated baseline staging with PET. Baseline PET/CT scans were reviewed centrally, and TMTV was calculated using the fixed threshold of SUV4. Kaplan–Meier and Cox regression were used for survival analysis. The primary study endpoint was Progression free Survival (PFS). A total of 689 FL patients were available for TMTV definition. Median TMTV was 161 mL (IQR 50 to 388 mL) and the best cutoff value was set at 180 mL. Patients with high TMTV had a significantly lower 5‐year PFS compared to those with low TMTV: 59% (95% CI, 53–65%) vs. 74% (95% CI, 69–78%) HR 1.61 (95% CI, 1.24–2.09). Prognostic role of TMTV was independent of study arm, chemotherapy regimen, and FLIPI2. Combined with FLIPI‐2, we identified three groups with different 5‐yr PFS rates, with the lowest rates (51%) for patients with high TMTV and high FLIPI2. Combined TMTV and FLIPI model was also prognostic to predict the risk of early progression and of death. Applying the SUV4 standard method pre‐treatment TMTV is confirmed as a strong and independent predictor of PFS in FL patients. Integrating TMTV with FLIPI‐2 improves risk assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularTumor BurdenHumansFemaleMaleMiddle AgedAgedPositron Emission Tomography Computed TomographyPrognosisAdultProspective StudiesProgression-Free Survival

Stichwörter der Autor:innen

FOLL12 trialPET/CTfollicular lymphomaprognosistotal metabolic tumor volume

Autor:innen und Institutionen

  • Nuclear Medicine, Azienda USL IRCCS of Reggio Emilia, Reggio Emilia, Italy.
  • Santa Croce e Carle Hospital, Medical Physics, Cuneo, Italy.
  • Hematology Unit, IRCCS Istituto Tumori 'Giovanni Paolo II' Bari, Bari, Italy.
  • IRCCS San Raffaele Scientific Institute, Nuclear Medicine, Milan, Italy.
  • Nuclear Medicine Division, S. Croce e Carle Hospital, Cuneo, Italy.
  • Fondazione Italiana Linfomi, Modena, Italy.

ORCID-Profile: Rexhep Durmo, Stephane Chauvie, Antonello Pinto, Alessandro Pulsoni, Pierluigi Zinzani

Förderung

  • Fondazione Italiana Linfomi (FIL)
  • Fellowship for Indigenous Leadership

Zitieren

APA

Durmo, R., Chauvie, S., Minoia, C., Bergesio, F., Fallanca, F., Peano, S., Marcheselli, L., Anastasia, A., Boccomini, C., Corradini, P., Olivieri, J., Arcaini, L., Cavallo, F., Ibatici, A., Nassi, L., Tarantino, V., Pinto, A., Stelitano, C., Pulsoni, A., …, & Luminari, S. (2025). Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub‐Study of the FOLL12 Trial. American Journal of Hematology. https://doi.org/10.1002/ajh.27711

Vancouver

Durmo R, Chauvie S, Minoia C, Bergesio F, Fallanca F, Peano S, et al. Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub‐Study of the FOLL12 Trial. American Journal of Hematology. 2025. doi:10.1002/ajh.27711

BibTeX
@article{Durmo2025,
  author = {Durmo, Rexhep and Chauvie, Stephane and Minoia, Carla and Bergesio, Fabrizio and Fallanca, Federico and Peano, Simona and Marcheselli, Luigi and Anastasia, Antonella and Boccomini, Carola and Corradini, Paolo and Olivieri, Jacopo and Arcaini, Luca and Cavallo, Federica and Ibatici, Adalberto and Nassi, Luca and Tarantino, Vittoria and Pinto, Antonello and Stelitano, Caterina and Pulsoni, Alessandro and Ricci, Francesca and Mancuso, Salvatrice and Cencini, Emanuele and Di Renzo, Nicola and Mannarella, Clara and Palmas, Angelo and Zinzani, Pierluigi and Bocci, Caterina and Rossi, Francesca and Carella, Angelo Michele and Federico, Massimo and Versari, Annibale and Guerra, Luca and Luminari, Stefano},
  title = {Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub‐Study of the FOLL12 Trial},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.27711}
}
Kostenlos starten →